meredith_regan_headshot

Meredith M. Regan, ScD, Promoted to Professor of Medicine

The Department of Data Science is delighted to announce that Meredith M. Regan, ScD, is promoted to Professor of Medicine as of October 1st.  

Dr. Regan is a graduate of Harvard TH Chan School of Public Health and joined our faculty in 2003. In addition to appointments at Dana-Farber and Harvard Medical School, Dr. Regan is Director of the International Breast Cancer Study Group Statistical and Data Management Center, centered at DFCI since 1977. Her research focuses on clinical-translational investigations to inform patient care and treatment selection for breast and genitourinary cancers and on clinical trial endpoints. She co-leads the IBCSG’s SOFT/TEXT trials which have changed care for premenopausal women with hormone receptor-positive early breast cancer. The DFCI-led ICECaP Working Group investigated surrogate endpoints of overall survival for localized prostate cancer trials and received the American Statistical Association’s 2021 SPAIG Award. She and colleagues proposed a treatment-free survival endpoint to measure durable remission arising from immunotherapy.

Dr. Regan is integral to statistical collaboration and faculty development at DFCI. She is a dedicated mentor to our biostatisticians and early career colleagues. She also serves as co-director of the DFCI Methods in Clinical Cancer Research prerequisite for all clinical trial PIs and sits on the Executive Committee for Clinical Research and Committee for Women Faculty (including 4 years as chair).  

Nationally and internationally, Dr. Regan’s leadership in developing and interpreting breast cancer clinical trials to improve patient care includes US NCI Breast Cancer and EBCTCG Steering Committees, ASCO and ESMO clinical guidelines committees, and St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. She is a frequent reviewer for ASCO, grants and clinical oncology journals; associate editor for JNCI Cancer Spectrum; a Breast Cancer Research Foundation (BCRF) sponsored researcher and Fellow of the American Society of Clinical Oncology.

COVID Data-Driven Policy: NC DHHS’s Use of Data for Pandemic Response

Frontiers in Biostatistics Seminar

Tuesday December 6, 2022
1:00PM Eastern Time

Register for Zoom link.

Jessie Tenenbaum, PhD
she / her / hers
Chief Data Officer
NC Department of Health and Human Services

Research Collaboration Wins 2022 Youden Award at JSM

The American Statistical Association named Roberta DeVito, PhD; Ruggero Bellio, PhD; Lorenzo Trippa, PhD; and Giovanni Parmigiani, PhD  as the recipients of the 2022 W.J. Youden Award. The award honors work developed at the Department of Data Science on multi-study factor analysis.

The authors propose a novel class of factor analysis methodologies for the joint analysis of multiple studies, published in Biometrics

The W. J. Youden Award in Interlaboratory Testing was “established in 1985 to recognize the authors of publications that make outstanding contributions to the design and/or analysis of interlaboratory tests or describe ingenious approaches to the planning and evaluation of data from such tests.”  The award is presented annually at the ASA Joint Statistical Meetings.

Artificial Intelligence Expert Bill Lotter, PhD Joins Data Science Faculty

The Department of Data Science faculty welcomes Bill Lotter, PhD on October 1, 2022.

Dr. Lotter joins Dana-Farber from DeepHealth Inc., a company he co-founded to improve diagnostic tools and outcomes in medical imaging. The company develops artificial intelligence (AI) software to assist radiologists, with a special focus on mammography. It was acquired in 2020 by RadNet Inc., the largest provider of outpatient imaging services in the United States.

As Chief Technology Officer of DeepHealth and Vice President of Machine Learning at RadNet, Dr. Lotter led the development of two FDA-cleared products that are now processing over 1 million mammograms per year. Dr. Lotter’s research has detailed the AI algorithms underlying these products, as well as their ability to aid in earlier breast cancer detection. He will bring his expertise in developing clinically-effective AI to novel applications within Dana-Farber.

“Building high-performing AI algorithms with clinical integration in mind can enable more widespread access to quality care,” said Dr. Lotter. “I’m excited to join the unique Dana-Farber ecosystem and collaborate on new AI applications to improve cancer care for all.”

Dr. Lotter will be Assistant Professor, Pathology Department at Harvard Medical School and an independent faculty member in Data Science. He received his PhD in Biophysics and Computational Science, where he developed computer vision algorithms for computational neuroscience in addition to medical imaging.

rafael irizarry dfci headshot

Rafael Irizarry, PhD, Named Lavine Family Chair for Preventative Cancer Therapies at Dana-Farber

Department Chair Rafael A. Irizarry, PhD, is the next incumbent to the Lavine Family Chair for Preventative Cancer Therapies at Dana-Farber. This chair is one of three endowed positions established by Dana-Farber Trustee Jonathan Lavine and his wife, Jeannie, through their extraordinary gift in 2020 to The Dana-Farber Campaign to leverage the Institute’s research efforts and develop comprehensive prevention and early detection models for all cancers.

As Chair of the Department of Data Science at Dana-Farber, Rafa leads efforts to collect, curate, develop methods, and analyze vast amounts of data that help improve treatments for patients. He is also a Professor of Biostatics at the Harvard T.H. Chan School of Public Health. He received his bachelor’s degree in mathematics from the University of Puerto Rico in 1993 and his PhD in statistics from the University of California, Berkeley in 1998. He joined Dana-Farber in 2013.

A renowned applied statistician committed to leveraging data to solve real-world problems, Rafa focuses on genomics and improving cancer care through data-driven approaches. Specifically, he has worked on the analysis and signal processing of data generated by emerging high-throughput technologies, which are technologies that sequence DNA and RNA in a rapid and cost-effective way. He is one of the founders of the Bioconductor Project, an open source and open development software project for the analysis of genomic data. Rafa has repeatedly been named in the Highly Cited Researchers list by the Institute for Scientific Information at Clarivate, most recently in 2021.

Rafa has received several awards for his excellence in the fields of statistics, computational biology, and bioinformatics. In 2009, the Committee of Presidents of Statistical Societies presented him with the Presidents’ Award, arguably the most prestigious award in statistics. In 2017, he was chosen as the laureate of the Benjamin Franklin Award in the Life Sciences by the members of Bioinformatics.org, which recognizes an individual dedicated to free and open access to materials and methods used in the life sciences. In 2020, he was named International Society of Computational Biology Fellow of the Year by the International Society of Computational Biology. Rafa is also deeply dedicated to teaching and mentoring the next generation of data scientists and has developed some of the most popular online courses on data analysis, sharing many of these materials freely online.

As a Lavine Family Chair for Preventative Cancer Therapies at Dana-Farber, Rafa will continue to collaborate with investigators across disease areas to find new prevention and detection strategies, enhance our efforts to maximize the latest advances in data science, and lead us in exploring a new frontier in cancer genomics.

– Dana-Farber Cancer Institute

Rochelle Levy-Christopher Receives 2022 Dana-Farber Community Service Award

Rochelle Levy-Christopher, Program Administrator with the Knowledge Systems Group, is the sole recipient of the 2022 Dana-Farber Community Service Award. Each year, this Institute-wide award recognizes “extraordinary dedication to and excellence in community service and outreach related to diversity, equity, and inclusion. It was established to honor “leaders of change, mentors to others, and those who contribute to the cultural and racial diversity of their community with great impact.” 

Originally from Harlem, New York, Ms. Levy-Christopher joined Data Science in 2018. In addition to managing the Knowledge Systems Group at Dana-Farber, Ms. Levy-Christopher serves as Scientific Project Coordinator for the Human Tumor Atlas Network Data Coordinating Center.

In 2019, Ms. Levy-Christopher launched The Black Literacy and Arts Collaborative (B.L.A.C.) Project, a 501(c)3, non-profit organization to educate, empower and uplift BIPOC youth and creatives at the intersection of art, culture, and activism. “By invoking radical imagination we encourage BIPOC communities to change landscapes all while inspiring new realities,” said Ms. Levy-Christopher. “Our goal is to support, educate and elevate BIPOC in order to create an equitable starting point between them and their white peers.”

In addition to her role as founder and CEO of The Black Literacy and Arts Collaborative Project, Ms. Levy-Christopher is a published poet, graphic designer and self-described “chronic entrepreneur and accidental activist,” dedicated to “Black Excellence ALWAYS.” She contributes to small BIPOC businesses and creatives by volunteering time to build brands, coach creatives, and entrepreneurs on the process of business startup and development as well as in her former role as Boston president of The Black Girl Social Club. Most recently, she has been recognized as a Forbes “For the Culture” member. 

“Among my friends, I have always been the “social” one,” says Ms. Levy-Christopher. “I act as the informal event planner, bringing women together, and making connections. I’ve spent the majority of my life teaching and mentoring marginalized youth, working especially with young womxn. My goal is to create access and equity for BIPOC while also empowering and inspiring Black womxn across the globe to walk in their purpose, speak their truth, and model authentic sisterhood for generations to come.”

meredith_regan_headshot

Meredith M. Regan, ScD, Recognized As 2022 ASCO Fellow

Meredith M. Regan, ScD, Associate Professor, received the distinction of FASCO, “Fellow of the American Society of Clinical Oncology” during the 2022 ASCO Annual Meeting. The FASCO distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO.

Dr. Regan led statistical collaboration for several studies presented at this year’s ASCO Annual Meeting, held June 3-6 in Chicago. Learn more about new breast cancer findings related to adjuvant endocrine therapy in high-risk subgroups:

 

Yiwen Liu, MS Wins 2021 Young Investigator Award

The American Journal of Hematology awarded Yiwen Liu, MS and collaborators with its 2021 Young Investigator Award. The honor is given annually to the first author(s) of one select publication.

Ms. Liu and co-authors Matthew L. Meizlish, George Goshua, and Rebecca Fine published one of the first studies on the use of intermediate anticoagulation and aspirin on the survival outcomes of in-hospital COVID patients. The findings reveal potential factors in the complicated decision making process of treating intermediate to severe COVID patients in the hospital setting in the early days of the pandemic.

Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis” first appeared in the American Journal of Hematology’s April 2021 issue.

“I am glad that my statistical expertise can help with decision-making in frontline COVID treatment therapies and this successful collaboration between the clinical team at Yale and the Data Science team at Dana-Farber,” says Liu.

Cancer Computational Methods Expert Martin Aryee, PhD Joins Data Science Faculty

The Department of Data Science at Dana-Farber Cancer Institute is excited to announce that Martin Aryee, PhD joins our faculty on January 1, 2022.

Dr. Aryee’s research involves the development and application of statistical methods for genomics. Most of his work centers on cancer epigenomics, with a focus on the role of spatial organization within tumors at scales ranging from DNA folding to the tumor microenvironment. He is also involved in the development of tools to ensure the safe translation of CRISPR-based genome editing technologies into clinical use. His research contributions include several methods for the analysis of DNA methylation data and insights into the role of disordered chromatin organization in cancer.

Dr. Aryee will be Associate Professor, Pathology Department at Harvard Medical School and an independent faculty member in Data Science. He will also lead a team of staff scientists as the Director of Hematologic Malignancies, Biostatistics and Computational Biology at Dana-Farber. He received his PhD in Biostatistics from the Harvard T.H. Chan School of Public Health, and completed his post-doctoral work at Johns Hopkins University School of Medicine.

The American Society of Hematology Honors Donna S. Neuberg with the 2021 Exemplary Service Award

(WASHINGTON, Oct. 5, 2021) – The American Society of Hematology (ASH) will recognize Donna S. Neuberg, ScD, senior statistician for the Leukemia, Lymphoma, and Benign Hematology Programs at Dana-Farber Cancer Institute, with the 2021 Exemplary Service Award for her years of service and dedication to ASH and to hematology.

The Exemplary Service Award was established in 1998 to recognize an individual whose outstanding service, extending over a period of years, has significantly advanced the interests of the Society. ASH President Martin S. Tallman will present this award during the 63rd ASH Annual Meeting and Exposition this December that will take place both in-person in Atlanta, Georgia, and virtually.

“Dr. Neuberg is an outstanding colleague and mentor as well as a world-class statistician with an encyclopedic knowledge of hematology. Through her decades of dedicated service in ASH training programs such as TRTH and CRTI, Dr. Neuberg has empowered innumerable investigators to design clinical trials with the highest standards of scientific rigor and statistical methodology,” said ASH President Martin S. Tallman of Memorial Sloan Kettering Cancer Center. “We value Dr. Neuberg’s contributions to shaping the future of hematology and of ASH.”

After receiving her ScD in Biostatistics from the Harvard School of Public Health, Dr. Neuberg joined the Dana-Farber Cancer Institute as a biostatistician. She currently serves as the senior statistician for the Leukemia, Lymphoma, and Benign Hematology Programs at Dana-Farber, where her research interests focus on the planning and analysis of studies that integrate laboratory outcomes at the genome, transcriptome, or proteome level with clinical and demographic information.

From 2014 to 2017, Dr. Neuberg served on the editorial board of Blood, ASH’s peer-reviewed journal. She has also demonstrated her commitment to ASH through her service as a statistician for the ASH Research Collaborative (ASH RC) Data Hub. Her expertise was integral in the development of the ASH RC COVID-19 Registry for Hematology data summaries, figures, and publications.

Dr. Neuberg has served as a dedicated mentor for the ASH-European Hematology Association (EHA) Translational Research Training in Hematology (TRTH), a year-long training program helping early-stage researchers build successful hematology research careers, since its inception in 2010. Dr. Neuberg is celebrated by TRTH participants for empowering trainees to take steps toward becoming not only rigorous scientists, but also thoughtful citizens of the international hematology community. In addition to celebrating the help they received in bringing their research to exceptional standards, trainees laud Dr. Neuberg for her generosity with her time and energy, and her ability to inspire them personally and professionally.

Dr. Neuberg’s deep passion for training the next generation of scientists is also reflected in her long-standing service as a mentor in the ASH Clinical Research Training Institute (CRTI), a year-long education program for hematology fellows and junior faculty at academic medical centers. She has shared her expertise as CRTI faculty from 2010 to 2016, and has participated in the study sections for the CRTI and the ASH Scholar Award. Her mentees and scholars credit her with imbuing them with her own unmistakable passion for sensible study design, experimental rigor, and enjoyment of a life in biomedical investigation.

Full press release from ASH Hematology